Biotechnology AG is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a pipeline of different
Immunodrug(TM) candidates in various disease areas, of which 6 are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis and Pfizer Animal
Health. Founded in 1995 as a spin-off from the Swiss Federal Institute of
Technology (ETH) in Zurich, the company is located in Schlieren (Zurich).
Currently, the company has 130 employees. Cytos Biotechnology AG has been
listed on the SWX Swiss Exchange (SWX:CYTN) since October 2002.
References
1. Journal of Hypertension, 2007, 25:63.
2. World Health Organization, Atlas of Heart Disease and Stroke, 2004.
3. Hypertension 2003; 42:1206.
4. New England Journal of Medicine, 1985, 313:1315.
5. Hypertension, 2006, 47:149.
6. Hypertension Research, 2006, 29:581.
7. American Journal of Hypertension, 2004, 17:347.
8. Hypertension, 2003, 42:1137.
Glossary
Ambulatory blood pressure: blood pressure measured continuously during
a normally active day; takes numerous automatic readings over a 24-hour
period or longer and applies non-invasive ambulatory blood pressure
monitoring devices.
Angiotensin II: a molecule of the RAS inducing vasoconstriction of
blood vessels and other effects to raise blood pressure.
Antibody: class of blood proteins generated by the immune system.
An
'/>"/>
SOURCE Cytos Biotechnology AG Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Strategic Diagnostics Updates Roth Conference Presentation Time2.
Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast3.
Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation4.
deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference5.
FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard6.
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference7.
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference8.
Volcano Corporation Presentation at Bear Stearns Conference to be Webcast9.
Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference10.
XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference11.
ZymoGenetics to Webcast Presentation at Two Upcoming Conferences